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A better understanding of the role of CD4
 
 
 
CD25
 
 
 
 regulatory T cells in disease pathogenesis 
should follow from the discovery of reliable markers capable of discriminating regulatory 
from activated T cells. We report that the CD4
 
 
 
CD25
 
 
 
 population in synovial fluid of 
juvenile idiopathic arthritis (JIA) patients comprises both regulatory and effector T cells that 
can be distinguished by expression of CD27. CD4
 
 
 
CD25
 
 
 
CD27
 
 
 
 cells expressed high 
amounts of FoxP3 (43% of them being FoxP3
 
 
 
), did not produce interleukin (IL)-2, 
interferon-
 
 
 
, or tumor necrosis factor, and suppressed T cell proliferation in vitro, being, on 
a per cell basis, fourfold more potent than the corresponding peripheral blood population. In 
contrast, CD4
 
 
 
CD25
 
 
 
CD27
 
 
 
 cells expressed low amounts of FoxP3, produced effector 
cytokines and did not suppress T cell proliferation. After in vitro activation and expansion, 
regulatory but not conventional T cells maintained high expression of CD27. IL-7 and IL-15 
were found to be present in synovial fluid of JIA patients and, when added in vitro, 
abrogated the suppressive activity of regulatory T cells. Together, these results demonstrate 
that, when used in conjunction with CD25, CD27 is a useful marker to distinguish regulatory 
from effector T cells in inflamed tissues and suggest that at these sites IL-7 and IL-15 may 
interfere with regulatory T cell function.
 
There is now clear evidence that a distinct popu-
lation of naturally occurring regulatory T cells,
which can be identified by the constitutive ex-
pression of CD4 and CD25, plays an essential
role in controlling autoimmunity (1). Regulatory
T cells are generated in the thymus or in pe-
riphery (2, 3) and, once activated, suppress other
T cells by an as yet uncharacterized contact-
dependent, cytokine-independent mechanism
(4). A functional result of suppression is impaired
production of IL-2 (4), although evidence has
been provided that an initial IL-2 production by
responder cells is necessary for expansion of
CD4
 
 
 
CD25
 
 
 
 T cells and induction of their sup-
pressor function (5). The suppressor function of
regulatory T cells can be relieved by exogenous
IL-2 that acts on both regulatory and responder
T cells and by IL-6 that blocks suppression at the
level of responder cells (6, 7).
The development and function of regula-
tory T cells is critically dependent on the tran-
scriptional repressor FoxP3 (8–10). Mice and
humans that lack Foxp3 die from severe au-
toimmune diseases (11–14), whereas trans-
duction of 
 
Foxp3
 
 in naive CD4
 
 
 
 T cells is
sufficient to convert these cells into regulatory
T cells (8, 9). Because 
 
Foxp3
 
 is the master con-
trol gene, it is in principle the most specific
marker for regulatory T cells. However, the
facts that FoxP3 is expressed exclusively intra-
cellularly and that reliable reagents for stain-
ing are not yet available prevent its use for the
identification and isolation of regulatory T
cells.
CD25 is the hallmark antigen of regulatory
T cells in mice and humans (15–19). In normal
conditions, CD25 appears to identify a rela-
tively homogeneous population of anergic reg-
ulatory T cells, although some heterogeneity
may exist. For instance, it has been reported
that among CD4
 
 
 
CD25
 
 
 
 T cells those express-
ing CD103 or CD62L are more suppressive than
their negative counterparts (20–22). Other
useful markers of regulatory T cells under normal
conditions include GITR, CTLA-4, and, in
mice, neuropilin-1 (23–25).
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There is growing interest in the identification of regula-
tory T cells in various pathological conditions and recent
studies indicate that CD4
 
 
 
CD25
 
 
 
 cells with regulatory
function can be indeed detected in inflamed tissues (26–28).
However, the identification of regulatory T cells in an ongo-
ing immune response or in inflamed tissues is complicated by
the fact that all the aforementioned markers, including
CD25, are also expressed on activated T cells (29). A possi-
ble heterogeneity of the CD4
 
 
 
CD25
 
 
 
 subset in inflamed tis-
sues has not been addressed so far and the problem, there-
fore, remains how to discriminate in an ongoing immune
response regulatory from activated effector T cells.
Here, we report that CD27 is stably expressed on regula-
tory T cells and can be used in conjunction with CD25 ex-
pression to discriminate in inflamed synovia regulatory T
cells, expressing high amounts of FoxP3 and endowed with
potent suppressive activity, from FoxP3
 
 
 
 effector T cells de-
void of suppressor activity. We also show that Il-7 and IL-15
are present in synovial fluid and in vitro abrogate the sup-
pressive function of regulatory T cells.
 
RESULTS
CD4
 
 
 
CD25
 
 
 
 T cells from synovial fluid of juvenile idiopathic 
arthritis (JIA) patients express high amounts of FoxP3 and 
show suppressor activity in vitro
 
Mononuclear cells were isolated from both synovial fluid
and peripheral blood of 15 JIA patients (7 with polyarticular
and 8 with oligoarticular disease course) and analyzed for the
expression of CD4 and CD25 (Fig. 1, A and B). The per-
centage of CD25
 
 
 
 cells within the CD4
 
 
 
 population ranged
from 4 to 11.6 (median, 8.6) in peripheral blood, a value
comparable to that found in healthy donors (not depicted),
whereas in synovial fluid it was significantly higher ranging
from 6.5 to 35.2 (median, 12.3; Fig. 1 B).
CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
 
 
 T cells were isolated by
cell sorting from blood and synovial fluid of the same individ-
ual and analyzed for expression of the transcription factor
FoxP3 using quantitative real-time PCR. FoxP3 mRNA was
higher in CD4
 
 
 
CD25
 
 
 
 as compared with CD4
 
 
 
CD25
 
 
 
 cells
in both peripheral blood and synovial fluid (Fig. 1 C). How-
ever, the amount of FoxP3 mRNA was much higher in the
two populations isolated from synovial fluid than in those iso-
lated from peripheral blood (Fig. 1 C). These findings suggest
that synovial CD4
 
 
 
CD25
 
 
 
 T cells may be activated in vivo
and that some regulatory T cells may be present within the
CD4
 
 
 
CD25
 
 
 
 subset. Indeed, upon in vitro stimulation pe-
ripheral blood CD4
 
 
 
CD25
 
 
 
 regulatory T cells, and to a
lower extent CD4
 
 
 
CD25
 
 
 
 T cells (30), rapidly up-regulated
FoxP3 mRNA (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20050085/DC1).
To examine the suppressive activity in vitro
 
,
 
 synovial and
peripheral blood CD4
 
 
 
CD25
 
 
 
 T cells were added at a 1:1
ratio to cultures of CFSE-labeled autologous peripheral blood
CD4
 
 
 
CD25
 
 
 
 responder T cells stimulated by DCs and anti-
CD3. As control, responder T cells were cultured in the ab-
sence or presence of unlabeled CD4
 
 
 
CD25
 
 
 
 T cells. 4 d
later, cultures were analyzed by FACS and the total number
of responder T cells that had performed one or more cell di-
visions was determined by CFSE dilution analysis. The per-
centage of suppression was calculated from the number of di-
viding responder cells in presence of CD4
 
 
 
CD25
 
 
 
 T cells
compared with their number in presence of CD4
 
 
 
CD25
 
 
 
control cells. As shown in Fig. 1 D, CD4
 
 
 
CD25
 
 
 
 T cells iso-
lated from blood or synovial fluid potently suppressed prolif-
eration of CD4
 
 
 
CD25
 
 
 
 T cells (93 and 98.3% inhibition,
respectively). We conclude that synovial fluid contains a large
population of CD4
 
 
 
CD25
 
 
 
 T cells characterized by high ex-
pression of FoxP3 and suppressor activity in vitro.
Figure 1. CD4 CD25  T cells are enriched in synovial fluid of JIA 
patients, express high amounts of FoxP3 mRNA, and efficiently sup-
press proliferation of CD4 CD25  autologous T cells. (A) Mononuclear 
cells from peripheral blood (PBMC) and synovial fluid (SFMC) were obtained 
from the same JIA patient and stained with antibodies to CD4 and CD25. 
Shown is the percentage of CD25  and CD25  cells within the CD4  
population. (B) Percentages of CD4 CD25  in PBMCs and SFMCs in 15 JIA 
patients. p-value determined by Wilcoxon rank test. (C) PBMCs and SFMCs 
were sorted based on expression of CD4 and CD25, and analyzed for 
expression of FoxP3 mRNA relative to 18S rRNA by quantitative real-time 
PCR. 1 representative experiment out of 10 is shown. (D) Proliferation of 
1.5   104 CFSE-labeled CD4 CD25  peripheral blood T cells stimulated by 
anti-CD3 and DCs in the presence of equal numbers of autologous 
CD4 CD25  T cells (unshaded histograms) or CD4 CD25  T cells (shaded 
histograms) isolated from PBMCs or SFMCs. The total number of responder 
T cells that had performed one or more cell divisions was determined by 
CFSE dilution analysis. Responder T cells proliferated to a similar extent in 
the absence of CD4 CD25  control T cells (not depicted). The percentage in-
hibition was calculated from the number of dividing responder cells in pres-
ence of CD4 CD25  T cells as compared with their number in presence of 
CD4 CD25  control cells. One representative experiment out of five is shown. 
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CD27 discriminates between regulatory and activated T cells 
in synovial fluid
 
Because CD25 is an activation marker, the pool of CD4
 
 
 
CD25
 
 
 
 cells in synovial fluid may contain not only regula-
tory T cells but also activated T cells. To dissect a possible
heterogeneity, we separated synovial CD4
 
 
 
CD25
 
 
 
 T cells
according to the expression of several cell surface markers
and used FoxP3 mRNA to monitor the presence of regula-
tory T cells. Subsets defined by presence or absence of
CTLA-4, CD62L, CD69, and GITR contained comparable
amounts of FoxP3 mRNA (Fig. 2 A). Similar data were ob-
tained using CCR4, VLA-4, and CD103 (unpublished data).
Thus, these markers, known to be expressed on circulating
regulatory T cells (16–19, 31–33), did not segregate with
FoxP3 expression in cells of inflamed synovia.
CD27 is a TNFR-family member that is expressed on
naive and subsets of memory T cells and is lost on terminally
differentiated effector T cells (34, 35). Because the latter are
highly enriched in synovial fluid of adult rheumatoid arthritis
and JIA patients (36, 37), we asked whether CD27 may dis-
criminate regulatory from activated effector T cells in in-
flamed joints. Indeed, in some synovial samples, we noted
that a high proportion (up to 50%) of CD4
 
 
 
CD25
 
 
 
 T cells
were CD27
 
 
 
 (Fig. 2 B and see Table II). CD4
 
 
 
CD25
 
 
 
CD27
 
 
 
 cells were also found in peripheral blood of patients
and healthy adults although at lower frequency (mean
15.6%, range 8.3–33 in 14 patients and 7.9%, range 2.6–11.3
in 5 controls).
The four subsets of CD4
 
 
 
 cells identified according to
the expression of CD25 and CD27 were isolated from the
synovia and blood of JIA patients and from the blood of
adult healthy controls and tested for FoxP3 mRNA expres-
sion. FoxP3 mRNA was at least 10-fold higher in CD4
 
 
 
CD25
 
 
 
CD27
 
 
 
 cells as compared with CD4
 
 
 
CD25
 
 
 
CD27
 
 
 
cells (Fig. 2 C and Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20050085/DC1). Low amounts of
FoxP3 mRNA were also found in CD4
 
 
 
CD25
 
 
 
CD27
 
 
 
 T
cells, whereas FoxP3 was not detected in CD4
 
 
 
CD25
 
 
 
CD27
 
 
 
 cells.
To estimate the frequency of FoxP3-expressing synovial
T cells within the four subsets, we used a sensitive PCR
method to detect FoxP3 in replicate samples containing lim-
iting numbers of T cells (five cells per sample). The highest
frequency of FoxP3
 
 
 
 cells (41.6%) was found in the
CD4
 
 
 
CD25 CD27  subset, whereas the CD4 CD25 
CD27  and the CD4 CD25 CD27  subsets showed much
lower frequencies (6.2% and 2.7%, respectively) and the
CD4 CD25 CD27  subset was negative (Fig. 3). Consider-
ing that frequencies are underestimated, these results suggest
that CD27 marks a rather homogeneous population of
FoxP3 expressing cells in inflamed synovia.
Figure 2. CD27 identifies FoxP3-expressing cells within CD25  
synovial CD4  T cells. (A) CD4 CD25  SFMCs were stained with anti-
bodies to CTLA-4, CD62L, CD69, and GITR. Positive and negative subsets 
were sorted and analyzed for FoxP3 mRNA. Mean   SD of three separate 
experiments. (B) PBMCs and SFMCs from patient 12 were stained with 
antibodies to CD4, CD25, and CD27. The histograms show the expression 
of CD27 on gated CD4 CD25  or CD4 CD25  T cells. (C) SFMCs were 
sorted according to the expression of CD4, CD25, and CD27 and analyzed 
for expression of FoxP3 mRNA. For comparison, the value in CD25 CD27  
was set to 100. Mean   SD of three separate experiments.
Figure 3. FoxP3 mRNA in CD4 CD25  T cell subsets in samples 
containing limiting cell numbers. CD4  T cell subsets were sorted 
according to the expression of CD25 and CD27 and resorted, collecting 
16 replicates of five cells each that were subsequently analyzed for 
expression of FoxP3 by PCR. Amplification of CD3 was used as control.CD25 CD27  REGULATORY T CELLS IN INFLAMED SYNOVIA | Ruprecht et al. 1796
GITR and CTLA-4 were expressed at comparable levels
on CD4 CD25 CD27  and CD4 CD25 CD27  cells,
whereas CD62L and CCR4 were expressed on a higher
proportion of CD27  cells (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20050085/DC1). In
addition, upon TCR triggering CD4 CD25 CD27  T cells
did not express IL-2, TNF, or IFN-  mRNAs, whereas
CD4 CD25 CD27  cells expressed high amounts of cyto-
kine mRNAs (Fig. S4, available at http://www.jem.org/cgi/
content/full/jem.20050085/DC1). Together, these findings
are consistent with the notion that CD4 CD25 CD27 
cells are regulatory cells, whereas CD4 CD25 CD27  rep-
resent activated effector cells.
To directly test the suppressive function, the four subsets
identified by the expression of CD25 and CD27 were iso-
lated by cell sorting from the synovial fluid and added to cul-
tures of CFSE-labeled peripheral blood CD4 CD25  T
cells. As shown in Fig. 4 A, suppressive activity was re-
stricted to the CD4 CD25 CD27  subset. The other three
subsets either did not interfere or even enhanced T cell pro-
liferation (Fig. 4 A). Synovial CD4 CD25 CD27  T cells
were, on a per cell basis, fourfold more potent as compared
with CD4 CD25 CD27  T cells isolated from peripheral
blood of the same patient (Fig. 4 B). We conclude that based
on four different criteria (expression of FoxP3 mRNA, ex-
pression of surface markers, lack of cytokine production, and
suppression of T cell proliferation) CD27 expression in the
context of CD25 expression allows discrimination of regula-
tory from activated/effector T cells in inflamed joints.
Figure 4. CD27 identifies potent suppressor cells within CD4 CD25  
synovial T cells. (A) Proliferation of CFSE-labeled CD4 CD25  peripheral 
blood T cells stimulated by anti-CD3 and DCs in the absence (dashed lines) 
or presence (solid line) of equal numbers of the indicated autologous 
CD4  T cells isolated from synovial fluid. The percentage inhibition was 
calculated as in Fig. 1. Comparable results were obtained using synovial 
T cells isolated from patient no. 14 (depicted) and nos. 2, 5, and 7. (B) Pro-
liferation of CFSE-labeled CD4 CD25  peripheral blood T cells in the 
presence of serial twofold dilutions of autologous CD4 CD25 CD27  
T cells from peripheral blood (open circle) or synovial fluid (closed square). 
Shown is the total number of responder T cells that had undergone more 
than one cell division. Mean   SD of triplicate cultures. Comparable 
results were obtained with samples from patient no. 15 (depicted) and 
nos. 5 and 7.
Figure 5. CD27 is stably expressed in proliferating regulatory 
T cells, whereas it is down-regulated on activated conventional T 
cells. (A) CD4 CD25 CD27  regulatory T cells and CD4 CD25 CD27 
T cells (comprising naive and memory cells) were sorted from peripheral 
blood to  99% purity. (B and C) Cells were labeled with CFSE and stim-
ulated with plastic-bound CD3 antibodies in the absence or presence of 
IL-2 or CD28 antibodies. CD27 expression was measured as a function of 
cell division on days 5 (B) and 10 (C). One representative experiment out 
of three performed is shown.JEM VOL. 201, June 6, 2005 1797
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CD27 is retained on regulatory T cells after 
activation and expansion
It is known that CD27 is lost upon terminal differentiation
of conventional CD4  T cells (34). To investigate whether
regulatory T cells may lose or retain CD27 expression
upon activation, we isolated CD4 CD25 CD27  regula-
tory T cells and CD4 CD25 CD27  naive and memory T
cells from peripheral blood (Fig. 5 A). Cells were labeled
with CFSE and stimulated with anti-CD3 in the absence or
presence of exogenous IL-2 or anti-CD28. As shown in
Fig. 5 (B and C), CD4 CD25  T cells proliferated exten-
sively and down-regulated CD27 expression as a function
of cell division. In contrast, CD4 CD25  regulatory T
cells proliferated poorly in the absence of IL-2, whereas
Figure 6. Differential distribution of CD25 CD27  regulatory and 
CD25 CD27  activated effector cells within synovial CD4  T cells 
of JIA patients with oligoarticular or polyarticular disease course. 
(A) Percentages of total CD4 CD25  T cells and CD27  and CD27  sub-
sets in 13 JIA patients with oligoarticular disease course (white bars) and 
12 JIA patients with polyarticular disease course (gray bars). (B) Ratio 
between regulatory and activated effector CD4  cells as defined by CD25 
and CD27 expression in oligoarticular (white bars) or polyarticular (gray 
bars) JIA patients. Boxes contain values falling between the 25th and 
75th percentiles. Lines that extend from the boxes represent the highest 
and the lowest values from each subgroup. The lines within the boxes rep-
resent median values. p-values were determined by Mann-Whitney U test. 
Also, see Table II for data from individual patients.
Figure 7. Distribution of CD4 CD25 CD27  regulatory T cells in 
lymph nodes and synovial tissues. (A–C) Serial sections of a reactive 
lymph node stained with antibodies to CD4 (A), CD25 (B), and CD27 (C). 
(D–H) Serial sections of synovial biopsy from a JIA patient showing a T and 
B lymphoid aggregate stained with antibodies to CD3 (D), CD20 (E), CD27 
(F), CD25 (G), and CD4 (H). (I) A consecutive section stained with CD25 
(red) and CD27 (green) by two-color fluorescence.CD25 CD27  REGULATORY T CELLS IN INFLAMED SYNOVIA | Ruprecht et al. 1798
they performed several cell divisions when exogenous IL-2
or costimulation was provided. Remarkably, in both con-
ditions, proliferating regulatory T cells retained high ex-
pression of CD27. We conclude that CD27 is a stable
marker of regulatory T cells that is retained after activation
and expansion.
Different proportions of CD4 CD25  subsets in JIA patients 
with polyarticular or oligoarticular disease
Some of the patients in this study had the disease limited to a
few joints (persistent oligoarticular), whereas others showed a
more aggressive polyarticular involvement (extended oligoar-
ticular, polyarticular, and systemic forms; Tables I and II). Al-
though the percentage of total CD4 CD25  cells did not differ
significantly between the two groups, the relative proportion of
CD27  and CD27  cells within the CD4 CD25  subset in af-
fected joints was significantly different (Fig. 6 A). Patients with
polyarticular disease showed higher proportion of CD27  acti-
vated/effector cells and slightly lower proportion of CD27 
regulatory T cells as compared with patients with oligoarticular
disease that showed a significantly higher ratio of regulatory to
activated cells (Fig. 6 B).
IL-7 and IL-15 are present in synovial fluid and limit 
the suppressor activity of regulatory T cells
Biopsies of synovial tissues were obtained from three JIA pa-
tients. When analyzed by immunohistochemistry, regulatory
T cells coexpressing CD4, CD25, and CD27 were found in
lymphoid aggregates (Fig. 7) consistent with the possibility
that they may participate in the ongoing immune response in
the inflamed tissue. To investigate the possibility that cyto-
kines that are present in the inflamed tissue may interfere with
regulatory T cell function, we tested a large panel of recom-
binant cytokines for their capacity to block the suppressive
function of regulatory T cells in vitro. The activity of regula-
tory T cells was strongly reduced in the presence of IL-2,
IL-7, and IL-15 and virtually abolished when IL-7 and IL-15
were added together (Fig. 8 A). In contrast, the proinflam-
matory cytokines IL-6, IL-12, TNF, and IFN- , as well as
another  -common–dependent cytokine, IL-4, were inef-
fective, whereas TGF-  and IL-10 showed direct suppres-
sive activity even in the absence of regulatory T cells (Fig. 8
A). Remarkably, IL-7 and IL-15 were detected in the syn-
ovial fluid of JIA patients, IL-7 being significantly higher in
patients with polyarticular as compared with patients with
Table I. Clinical characteristics of JIA patients included in the study
Patient Sex JIA form Age Disease duration No. active jointsa ESR Treatment
yr yr mm/first hour
1 F polyarticular RF- 6.2 3.5 25 20 MTX, CyA
2 F extended oligoarticular 2.8 0.9 20 36 NSAID
3 F extended oligoarticular 9.5 7.1 2 96 MTX
4 F polyarticular RF- 5.4 0.8 27 53 NSAID
5 F extended oligoarticular 10.4 9.3 7 34 MTX
6 M systemic 4.3 1.7 4 97 MTX, CS
7 F extended oligoarticular 5.1 3.2 3 25 MTX
8 F extended oligoarticular 6.9 5.0 2 24 MTX
9 F polyarticular RF- 5.2 1.9 8 20 MTX, NSAID
10 F extended oligoarticular 6.3 5.2 6 60 MTX
11 F polyarticular RF- 9.9 8.5 3 34 CyA, NSAID
12 F systemic 10.3 0.8 16 96 MTX, NSAID
13 F persistent oligoarticular 8.5 7.1 4 12 -
14 M persistent oligoarticular 4.2 2.1 1 11 NSAID
15 F persistent oligoarticular 12.9 4.7 1 11 NSAID
16 F persistent oligoarticular 4.0 1.3 2 13 NSAID
17 F persistent oligoarticular 2.5 1.1 1 11 NSAID
18 F persistent oligoarticular 9.3 6.2 3 14 NSAID
19 F persistent oligoarticular 2.9 1.6 2 25 -
20 F persistent oligoarticular 11.9 3.1 1 26 NSAID
21 F persistent oligoarticular 6.0 1.6  2 36 -
22 F persistent oligoarticular 3.6 1.9 2 14 NSAID
23 F persistent oligoarticular 6.7 5.8 1 18 NSAID
24 F persistent oligoarticular 8.1 3.6 2 26 NSAID
25 M persistent oligoarticular 14.2 9.3 1 12 NSAID
aDefined as presence of swelling and/or limitation of motion with tenderness.
CS, corticosteroids, CyA, cyclosporin A; ESR, erythrocyte sedimentation rate; MTX, methotrexate; NSAID, nonsteroidal antiinflammatory drugs; RF, rheumatoid factor.JEM VOL. 201, June 6, 2005 1799
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oligoarticular disease (Fig. 8 B). Together, these results sug-
gest that in inflamed tissues IL-7 and Il-15 may substantially
limit the suppressor function of regulatory T cells.
DISCUSSION
In this study, we addressed the problem of identifying natu-
rally occurring regulatory T cells in inflamed tissues. We
found that in synovial fluid of JIA patients, CD27 expression
can be used to discriminate, within the CD4 CD25  subset,
regulatory T cells from activated effector T cells. CD27 is
expressed on regulatory T cells in both peripheral blood and
synovial tissues and is retained by these cells after activation
and clonal expansion in vitro, whereas CD27 is absent on ef-
fector T cells and is rapidly lost on CD27  naive and mem-
ory T cells after activation (38, 39). Thus, although CD27 is
not a specific marker for regulatory T cells, the differential
regulation of expression in regulatory and conventional T
cells makes it a suitable marker for the identification of regu-
latory T cells in inflamed tissues.
The intensity of CD25 expression is considered a reliable
marker for regulatory T cells in peripheral blood (16). How-
ever, this may not be sufficient to identify regulatory T cells
in inflamed tissues. Indeed, a recent study demonstrated that
CD25dim cells from synovial fluid express FoxP3 and have
suppressive activity (40). In this regard, we found that CD27
is expressed not only on all CD25bright cells, but also on a
sizeable proportion of CD25dim cells and that CD25dim
CD27  and CD25brightCD27  T cells express comparable
amounts of FoxP3 mRNA (unpublished data). We conclude
that the combination of CD25 and CD27 allows identifica-
tion of most of regulatory T cells, while effectively exclud-
ing effector T cells.
Growing evidence over the past few years indicates that
CD27, as well as other members of the TNFR family, such
as OX40 (CD134) and 4-1BB (CD137), plays an important
role for the effective generation of many types of T cell re-
sponses (41). It remains to be established what role CD27
may play in regulatory T cell function and whether sustained
expression of CD27 on regulatory T cells contribute to their
maintenance in vivo.
Using limiting dilution analysis, we could estimate that
41% of CD4 CD25 CD27  T cells isolated from inflamed
Table II. Distribution of CD27 in synovial CD4 CD25  and CD4 CD25  T cells subsets in JIA patients with oligoarticular and 
polyarticular disease course
CD4  Percentage of CD27  in:
Patient Disease course CD25 CD27  CD25 CD27  CD25 CD27  CD25 CD27  CD4 CD25  CD4 CD25 
1 polyarticular 16.8a 9.7a 48a 24.9a 36.5b 34.1c
2 polyarticular 6.8 4.3 42.7 46.2 38.7 52.0
3 polyarticular 11.2 5.8 23.3 59.7 34.1 41.1
4 polyarticular 6.3 3.4 43 47.6 35.1 52.5
5 polyarticular 8.7 4.2 42 45 32.6 51.7
6 polyarticular 8.1 5.6 57.2 29.0 40.9 33.6
7 polyarticular 7.5 1.4 39.7 51.4 15.7 56.4
8 polyarticular 5.3 1.2 76 17.3 18.4 18.5
9 polyarticular 32.3 2.9 19.7 43 8.2 68.5
10 polyarticular 8.3 2.4 27.7 61 22.4 68.8
11 polyarticular 10.5 2.2 68.2 19 17.3 27.0
12 polyarticular 7.7 8.4 39 44.2 52.2 53.1
13 oligoarticular 9.1 2.7 32 55 22.9 63.2
14 oligoarticular 10.7 1 85 4.9 8.5 5.4
15 oligoarticular 16 1.2 73 8 7.0 9.9
16 oligoarticular 33 1.2 54 11.5 3.5 17.5
17 oligoarticular 6.8 3 36 54 30.6 60.0
18 oligoarticular 7.3 3.6 50 38 33.0 43.2
19 oligoarticular 16.9 1.5 56 25 8.1 30.9
20 oligoarticular 9.9 1.2 68.8 20 10.8 22.5
21 oligoarticular 9.0 1.7 55 34 15.9 43.0
22 oligoarticular 10.2 1.8 56 31 15.0 35.6
23 oligoarticular 11.0 0.5 71 17 4.3 19.3
24 oligoarticular 7.6 1.1 62 28 12.6 31.1
25 oligoarticular 13.6 1.1 63 23 11.1 26.7
aPercentages within CD4  synovial cells.
bPercentages within CD4 CD25  synovial cells.
cPercentages within CD4 CD25  synovial cells.CD25 CD27  REGULATORY T CELLS IN INFLAMED SYNOVIA | Ruprecht et al. 1800
joints express FoxP3. The possibility of isolating a rather ho-
mogeneous population of regulatory T cells from inflamed
tissues was instrumental to establish their relative potency as
compared with regulatory T cells from peripheral blood. A
direct comparison of regulatory T cells from synovial fluid
and peripheral blood of the same patient revealed that syn-
ovial regulatory T cells expressed much higher levels of
FoxP3 and were on a per cell basis fourfold more potent in
suppressing T cell proliferation than peripheral blood regula-
tory T cells. As activation by anti-CD3 and IL-2 increases
both FoxP3 expression and suppressor function of peripheral
blood regulatory T cells (42), these findings suggest that the
increased potency of synovial regulatory T cells is a conse-
quence of their activated state in vivo.
The relevance of discriminating regulatory from effector
T cells in inflamed tissues is underlined by our finding that,
in the joints of JIA patients, up to 50% of CD4 CD25  T
cells were CD27  effector T cells and that the ratio of regu-
latory to activated T cells was higher in patients with oli-
goarticular disease course than in those with severe poly-
articular disease course. Because the contamination of
activated T cells in the CD25  population can be substantial
and varies with disease state, it will be important to reassess
the presence of regulatory T cells in other pathological tis-
sues (26, 28) by using a combination of markers as those de-
scribed in the present study.
Although regulatory T cells can be found in tissues un-
dergoing chronic inflammation it remains to be established
whether they exert their function in vivo. Besides possible
intrinsic defects in regulatory T cells (43–45), there may be
several mechanisms that limit the efficacy of regulatory T cells
in peripheral inflamed tissues. For instance, in vitro preacti-
vated T cells become resistant to suppression and this resis-
tance is dependent on the strength and duration of the stimu-
lus (28, 42). We also found that naive T cells become
completely refractory to suppression 24 h after TCR stimula-
tion (unpublished data). In addition, exogenous signals such
as those provided by GITR-L and IL-6 render responsive T
cells resistant to suppression mediated by CD4 CD25  regu-
latory T cells (7, 46). We screened a large panel of cytokines
for their capacity to relieve suppression in vitro and found
that IL-7 and IL-15, and more effectively a combination of
the two, can counteract the suppressor function of regulatory
T cells. Based on these results and on the finding that both
IL-7 and IL-15 can be detected in the joint fluid of JIA pa-
tients, we suggest that in target tissues the function of regula-
tory T cells may be substantially limited by these cytokines
and that therapies that aim at neutralizing such cytokines may
not only decrease bystander T cell activation but also recon-
stitute the suppressor function of regulatory T cells.
MATERIALS AND METHODS
Patients.  25 consecutive JIA patients diagnosed according to ILAR
Durban’s criteria (47) were included in the study. All patients had active
disease and underwent synovial fluid aspiration for steroid injection. To
be included in the study, patients with persistent oligoarticular course
should have presented a disease duration  1 yr. In all cases, a steroid in-
jection in the same joint in the previous 6 mo was considered as an exclu-
sion criterion. The patients tested in the functional studies were under
NSAID and/or methotrexate treatment. The main clinical and laboratory
features and the ongoing treatment at the moment of the study are re-
ported in Table I. Patients’ samples were taken after parents’ permission
according to the informed consent approved by the ethical committee of
the G. Gaslini Institute.
Media and reagents.  The medium used throughout the experiments was
RPMI 1640 supplemented with 10% fetal calf serum, 1% Glutamax, 1%
nonessential amino acids, 1% pyruvate, 50 U/ml penicillin, 50  g/ml strep-
tomycin (all obtained from Invitrogen), and 5   10 5 M 2-mercaptoethanol
(Merck). Recombinant human IL-6, IL-7, IL-10, IL-12, IL-15, IFN- ,
Figure 8. IL-7 and IL-15 counteract the suppressor activity of 
regulatory T cells and are present in synovial fluid of JIA patients. 
(A) Proliferation of CFSE-labeled CD4 CD25  peripheral blood T cells 
stimulated by TSST-pulsed DCs in the absence (unshaded histograms) or 
presence (shaded histograms) of equal numbers of the CD4 CD25  T 
cells. The cultures were set up in medium alone (no cytokines) or in 
medium supplemented with the indicated cytokines. (B) IL-7 and IL-15 
were quantified by ELISA in sera and synovial fluid (SF) from 15 oligoar-
ticular (white bars) and 15 polyarticular (gray bars) JIA patients and in 
sera from 12 age-matched healthy controls (black bars). Boxes contain 
values falling between the 25th and 75th percentiles. Lines that extend 
from the boxes represent the highest and the lowest values from each 
subgroup. The lines within the boxes represent median values. p-values 
were determined by Mann-Whitney U test.JEM VOL. 201, June 6, 2005 1801
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TNF, and TGF-  were purchased from BD Biosciences. IL-2 and IL-4 were
produced in our laboratory using the myeloma-based expression system.
FACS analysis. The following monoclonal antibodies were used: mouse
CD4-FITC, CD4-APC, CD27-FITC, CD27-PE, CD62L-PE, CD69-PE,
CTLA4-PE, CCR4-PE (all obtained from Becton Dickinson), CD25-
FITC (DakoCytomation), CD25-PE (Miltenyi Biotec), and GITR-PE
(R&D Systems).
Cell isolation. PBMCs and synovial fluid mononuclear cells (SFMCs)
were isolated by Ficoll-Hypaque (Sigma-Aldrich) density gradient centrifu-
gation. After staining for various surface markers, subpopulations of CD4 
T cells were sorted by FACSVantage (Becton Dickinson). Purity of cell
preparations was typically  97%. Monocytes were isolated from PBMCs by
positive selection using CD14 microbeads (Miltenyi Biotec). The purified
monocytes were cultured for 3–5 d in RPMI 1640 10% FCS containing 50
ng/ml GM-CSF (Leukomax; Novartis) and 1,000 U/ml IL-4.
Proliferation assay. Peripheral blood CD4 CD25  T cells were labeled
with 0.5  M CFSE (Molecular Probes) for 8 min at room temperature. Af-
ter quenching of the labeling reaction by addition of RPMI 1640 10% FCS,
cells were washed extensively. 1.5   104 cells were cultured alone or to-
gether with different numbers of unlabeled regulatory or control cells in the
presence of 103 immature DCs and either 2 ng/ml TSST (Toxin Technol-
ogy) or 0.25 ng/ml CD3 antibodies (supernatant from clone OKT3). Prolif-
eration was measured on day 4 on a FACSCalibur (Becton Dickinson) using
propidium iodide (Sigma-Aldrich) to exclude dead cells. In some experi-
ments, T cells were stimulated with plate-bound CD3 antibodies (2  g/ml,
from clone TR66) in the absence or presence of 100 U/ml of recombinant
IL-2 or 2  g/ml plate-bound CD28 antibodies (BD Biosciences).
Real-time PCR. For quantitative assessment of relative mRNA levels,
total RNA was prepared from sorted subpopulations using TRIzol LS re-
agent (Invitrogen) according to the manufacturer’s instructions. RNA was
reverse transcribed using M-MLV RT reverse transcription kit with ran-
dom hexamer primers (Invitrogen). The relative level of FoxP3 mRNA in
each subset was determined by real-time PCR on an ABI PRISM 7700 se-
quence detector (Applied Biosystems) using the Assay-On-Demand product
for FoxP3 detection (Hs00203958_m1) and universal PCR master mix
(both obtained from Applied Biosystems). The obtained values were nor-
malized to the amount of 18S rRNA (4310893E; Applied Biosystems)
present in each sample. For detection of relative cytokine mRNA levels,
sorted T cell subsets were stimulated for 6 h with 50 nM phorbol 12,13-
dibutyrate (PdBu; Sigma-Aldrich) and 1  g/ml anti-CD3 (clone TR66)
before extraction of total RNA. Cytokine mRNA levels were deter-
mined  using Applied Biosystems products for IL-2 (4309882P), TNF
(Hs00174128_m1), and IFN-  (4327052F).
Cytokine detection assays. IL-7 and IL-15 were measured using com-
mercial ELISA (R&D Systems) in the sera and synovial fluid of 30 JIA pa-
tients (15 with oligoarticular course and 15 with polyarticular course) and in
sera of 12 age-matched controls that were obtained for routinely preopera-
tive examination before minor surgery. The assay detection limit was 0.1
pg/ml for IL-7 and 2 pg/ml for IL-15.
Five-cell PCR. For determination of FoxP3 mRNA at a five-cell level, the
four CD4  T cell subsets were first sorted by flow cytometry. From each of the
purified subpopulations, five-cell aliquots were resorted directly into wells of a
96-well conic plate. The subsequent procedures for cDNA preparation and
nonspecific cDNA amplification were performed as described by Bigouret et al.
(48). 1  l of the nonspecifically amplified cDNA was used to amplify FoxP3
cDNA with 0.5  M of the specific primers FoxP3-F (5 -CACCTACGC-
CACGCTCATC-3 ) and FoxP3-R (5 -ACTCAGGTTGTGGCGGATG-
3 ) (both obtained from Microsynth) in presence of 1.5 mM MgCl2. As a con-
trol, the expression of CD3 was assessed using the primers CD3 S1 (5 -CGT-
TCAGTTCCCTCCTTTTCTT-3 ) and CD3 AS1 (5 -GATTAGGGGGT-
TGGTAGGGAGTG-3 ) (Microsynth). The program used for amplification
was 3 min at 94 C; 30 s at 94 C, 30 s at 58 C, 30 s at 72 C, 40 cycles.
Immunohistochemistry. Tissue specimens were prepared for immuno-
histochemistry according to standard technique. In brief, specimens were
fixed in 10% formalin for 4 h, dehydrated, and embedded in paraffin. Paraf-
fin serial sections were stained for 30 min at room temperature with mouse
antibodies to CD4 (4B12), CD25 (25C04), CD27 (137B4; obtained from
Neomarkers), CD20 (L26), and CD3 (polyclonal antisera; obtained from
DakoCytomation) followed by anti–mouse Ig antibody conjugated to per-
oxidase-labeled dextran polymer (EnVision; DakoCytomation) and chro-
mogenic diaminobenzidine substrate (DakoCytomation). Slides were coun-
terstained with Mayer’s hematoxylin. For double immunofluorescence,
secondary labeling was performed for 30 min at room temperature with Al-
exa Fluor 594 goat anti–mouse IgG2b (Molecular Probes) and, subse-
quently, with Alexa Fluor 488 goat anti–mouse IgG1 (Molecular Probes) to
label CD25 and CD27, respectively.
Statistical analysis. Differences in the percentages of matched peripheral
blood and synovial fluid CD4 CD25  T cells were analyzed by the Wil-
coxon matched pairs signed rank test. Differences in the percentages of
CD4 CD25 CD27  and CD4 CD25 CD27  and in the amounts of IL-7
and IL-15 in oligoarticular and polyarticular JIA patients were analyzed by
Mann-Whitney U test.
Online supplemental material. Fig. S1 shows the kinetics of FoxP3
mRNA accumulation in peripheral blood CD4 CD25 regulatory T cells and
CD4 CD25  naive and memory T cells upon TCR stimulation. Fig. S2 de-
picts the amount of FoxP3 mRNA in peripheral blood CD4  T cells sorted
from JIA patients and adult healthy donors according to the expression of CD25
and CD27. Fig. S3 shows the expression of markers associated with regulatory
T cells on the synovial CD4 CD25 CD27  and CD4 CD25 CD27  subset.
Fig. S4 depicts the amount of cytokine mRNA produced by synovial CD4  T
cell subsets isolated according to the expression of CD25 and CD27 upon TCR
stimulation. Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20050085/DC1.
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